Entropy Technologies’s Apellis Pharmaceuticals APLS Stock Holding History

Entropy Technologies’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-23,128	Closed	-$581K	–	875
2025 Q4	$581K	Sell	23,128 -1,475	-6%	-$34.6K	0.03%	521
2025 Q3	$557K	Buy	+24,603	New	+$574K	0.04%	488
2025 Q1	–	Sell	-13,960	Closed	-$445K	–	715
2024 Q4	$445K	Buy	+13,960	New	+$420K	0.05%	456

Other funds holding APLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Entropy Technologies's APLS Position: Q1 2026 in Review

Entropy Technologies sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 23,128 shares — an estimated $581K sold.

Entropy Technologies first reported a position in APLS in Q4 2024 and held it in 3 quarters. The position peaked at $581K in Q4 2025. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

Entropy Technologies reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Entropy Technologies sold 23,128 Apellis Pharmaceuticals shares in Q1 2026, an estimated $581K.
Entropy Technologies first reported a position in Apellis Pharmaceuticals in Q4 2024 and held it in 3 quarters.
Entropy Technologies's Apellis Pharmaceuticals position peaked at $581K in Q4 2025.
323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Entropy Technologies's 13F filing for Q1 2026, filed 14 May 2026.